ResMed Inc. (RMD) Stock: The Sleep Apnea Leader Facing a New Awakening
- 4 days ago
- 6 min read
For three decades, ResMed has been the undisputed global leader in a quiet but massive healthcare market: the treatment of sleep apnea. The company has built a dominant and highly profitable empire by developing the devices and masks that help millions of people breathe better at night, transforming a once-obscure condition into a widely recognized chronic disease. Its business model is a textbook example of a durable, recurring revenue machine that has delivered consistent growth and impressive returns for long-term investors.
However, the ground is now shifting under this sleep therapy giant. The market has been reshaped by a massive competitor recall that handed ResMed a huge, temporary windfall. More profoundly, the rise of a new class of revolutionary weight-loss drugs—the GLP-1 agonists like Ozempic and Zepbound—has cast a shadow of uncertainty over the entire sleep apnea industry, raising fundamental questions about its future.
This has created one of the most compelling and controversial debates in the MedTech sector. Is ResMed an industry leader facing an existential threat, or is the market overreacting, creating a rare opportunity to buy a best-in-class company at a discount? This in-depth analysis will dissect the investment case for ResMed, from its foundational business to the monumental challenges and opportunities that lie ahead.
A Legacy of Breath: Pioneering Sleep Apnea Treatment
ResMed’s story begins in the 1980s with a groundbreaking medical innovation. Professor Colin Sullivan and his colleagues at the University of Sydney, Australia, developed the first continuous positive airway pressure (CPAP) device, a machine that uses mild air pressure to keep a patient's airway open during sleep. This was the first effective, non-invasive treatment for obstructive sleep apnea (OSA).
Dr. Peter Farrell, a visionary entrepreneur, recognized the immense commercial potential of this technology. In 1989, he founded ResMed to commercialize the CPAP machine and bring this life-changing therapy to the world.
From its earliest days, ResMed’s culture has been one of continuous innovation, focused on making CPAP therapy more comfortable, effective, and user-friendly. The company has a long history of breakthroughs that have set the standard for the industry:
Improving the Algorithm: Developing sophisticated auto-titrating positive airway pressure (APAP) devices, like its flagship AirSense line, that can automatically adjust the pressure level throughout the night to meet a patient’s specific needs.
Revolutionizing Mask Design: Engineering smaller, lighter, and more comfortable masks that have dramatically improved patient compliance and a willingness to stick with the therapy.
Pioneering Digital Health: ResMed was one of the first MedTech companies to build a cloud-based digital health ecosystem. Its AirView software platform allows doctors and durable medical equipment (DME) providers to remotely monitor patient data, track compliance, and adjust settings, creating a powerful, connected care network.
This history of innovation has allowed ResMed to build a trusted brand and a dominant market position, making it the go-to choice for sleep physicians and patients around the world.
The Business Model: A High-Margin Recurring Revenue Machine
ResMed’s business is a classic "razor-and-blade" model, creating a highly predictable and profitable stream of recurring revenue.
1. Devices (The "Razors"): The first step is the sale of a CPAP or APAP device, most notably its market-leading AirSense platform (currently the AirSense 10 and 11). These smart, connected devices are the foundation of the ecosystem.
2. Masks and Accessories (The "Blades"): This is the heart of the business and the primary profit driver. To use the device, a patient needs a mask, and these masks are disposable medical products that need to be replaced regularly (typically every 3-6 months) to ensure proper hygiene and an effective seal. This creates a massive and continuous annuity stream of high-margin revenue for every device sold. In fact, mask sales account for a larger portion of the company’s revenue than the devices themselves.
3. Software-as-a-Service (SaaS): This is a rapidly growing and increasingly important part of the business. ResMed provides a suite of software solutions, like AirView for providers and the myAir app for patients, that enhance the value of its ecosystem. This digital platform not only improves patient outcomes but also creates high switching costs, locking customers into the ResMed ecosystem.
This model is incredibly powerful. The global market for sleep apnea is enormous and vastly underdiagnosed—it is estimated that nearly 1 billion people worldwide suffer from OSA, with more than 80% of them undiagnosed. Every new patient diagnosed and placed on a ResMed device represents a multi-year stream of high-margin, recurring mask revenue.
Navigating a Shifting Landscape: The Philips Recall and the GLP-1 Threat
The last few years have been a period of unprecedented upheaval for the sleep apnea market, driven by two major external events.
The Philips Recall Windfall
In 2021, ResMed’s primary global competitor, Philips Respironics, initiated a massive recall of millions of its CPAP and ventilator devices due to potential health risks from sound abatement foam. This effectively removed ResMed’s biggest rival from the market for an extended period.
As a result, ResMed was handed a massive, temporary surge in demand. The company captured a huge amount of market share as patients and providers scrambled for an alternative. This "recall windfall" led to a period of supercharged growth for ResMed, but it also creates very difficult year-over-year financial comparisons as Philips slowly begins to re-enter the market.
The GLP-1 Threat: Existential Risk or Overblown Fear?
The most significant long-term question facing ResMed is the impact of the new class of highly effective weight-loss drugs known as GLP-1 agonists (e.g., Ozempic, Wegovy, Zepbound).
Obstructive sleep apnea is strongly correlated with obesity. Excess weight, particularly around the neck, is a primary cause of airway collapse during sleep. The thesis that has terrified investors and weighed heavily on ResMed’s stock is that if these drugs lead to widespread, significant weight loss, it could:
Reduce the severity of OSA in existing patients, potentially decreasing their need for CPAP therapy.
Prevent the onset of OSA in people who would have otherwise developed it, shrinking the pool of future new patients.
However, the bull case for ResMed argues that this threat is overstated. They point out that:
Weight loss does not "cure" sleep apnea for everyone, and many patients will still require therapy.
The high cost and potential side effects of GLP-1 drugs may limit their long-term, widespread use.
These drugs could actually increase the number of diagnoses, as patients engaging with their doctors about weight loss are more likely to be screened for associated conditions like OSA.
This debate is the central issue that will determine the long-term trajectory of ResMed’s stock.
Financials: A Consistent Performer Facing Uncertainty
Historically, ResMed’s financial performance has been a model of consistency.
Durable Growth: For years, the company has reliably delivered high single-digit to low double-digit revenue growth, driven by the steady expansion of the sleep apnea market and market share gains.
High Profitability: The company enjoys excellent, high-margin profitability, a direct result of its lucrative recurring revenue from mask sales.
Dividend Growth: ResMed is a consistent dividend payer and has a track record of increasing its dividend every year, making it an attractive holding for dividend growth investors.
However, the recent market dynamics have introduced a new level of uncertainty into its financial outlook. The stock's valuation has compressed significantly from its historical highs as the market has tried to price in the long-term risk from GLP-1 drugs.
Fundamental Data
Go beyond the stock price with this deep dive into a company's core fundamentals.
🔖 Key Takeaways
The decision to invest in ResMed today is a decision about how you view the long-term impact of GLP-1 drugs on the sleep apnea market. It is an investment in a best-in-class market leader facing its most significant potential disruption.
For the Contrarian/Value Investor: ResMed presents a compelling opportunity. The thesis is that the market has overreacted to the GLP-1 threat, creating a rare chance to buy a high-quality, wide-moat business at a discounted valuation. You get a solid, growing dividend while waiting for the market's fears to subside. This investor believes the underlying market for sleep apnea is durable and that the impact of weight-loss drugs will be manageable.
For the Growth-Focused but Risk-Averse Investor: This is a more challenging proposition. While ResMed has a strong historical growth record, the uncertainty created by GLP-1s clouds the future growth trajectory. This type of investor might prefer to wait on the sidelines until there is more clarity—either from clinical data or market trends—on how this major secular shift will play out.
ResMed is a phenomenal business that has been a leader in its field for decades. Its dominant market position and powerful recurring revenue model are undeniable strengths. However, the company is at a pivotal moment, caught between the tailwinds of a massive, underdiagnosed market and the potential headwinds of a new class of blockbuster drugs. For investors who believe the GLP-1 fears are overblown, ResMed offers a compelling opportunity to own a world-class company at a reasonable price.
This was the ResMed (RMD) Stock: The Sleep Apnea Leader Facing a New Awakening. Want to know which healthcare stocks are part of the S&P 500? Click here.
Comments